Immediate Impact
3 from Science/Nature 68 standout
Citing Papers
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
2024 Standout
Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial
2024 Standout
Works of Antonio D’Alessio being referenced
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape?
2022
Preliminary results from a phase Ib study of neoadjuvant ipilimumab plus nivolumab prior to liver resection for hepatocellular carcinoma: The PRIME-HCC trial.
2022
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Antonio D’Alessio | 231 | 278 | 116 | 433 | 410 | 103 | 1.5k | |
| J. Medina | 44 | 182 | 34 | 293 | 46 | 105 | 2.0k | |
| M. Nakahara | 50 | 113 | 41 | 416 | 20 | 118 | 1.8k | |
| Masaru Hirata | 49 | 92 | 31 | 49 | 26 | 127 | 1.7k | |
| C. Renard | 45 | 15 | 157 | 124 | 45 | 44 | 1.2k | |
| Robert A. Fletcher | 6 | 11 | 53 | 560 | 477 | 76 | 1.9k | |
| Ken‐ichi Nomura | 168 | 26 | 58 | 25 | 47 | 122 | 1.9k | |
| Timothy Hughes | 11 | 11 | 20 | 403 | 91 | 23 | 1.4k | |
| Y. Higashi | 31 | 11 | 49 | 601 | 115 | 151 | 2.2k | |
| A. D’Alessio | 29 | 6 | 12 | 856 | 631 | 73 | 1.5k | |
| Fredrik Carlsson | 34 | 39 | 38 | 19 | 43 | 66 | 1.9k |
All Works
Login with ORCID to disown or claim papers
Loading papers...